[8-K] PFIZER INC Reports Material Event

Rhea-AI Filing Summary

Pfizer Inc. filed an 8-K announcing its third-quarter 2025 financial results. The company furnished a press release as Exhibit 99 dated November 4, 2025, detailing the quarter’s performance. The information under Item 2.02 (Results of Operations and Financial Condition) is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings except by specific reference. An Inline XBRL cover page file is also included as Exhibit 104.

0000078003false00000780032025-11-042025-11-040000078003us-gaap:CommonStockMember2025-11-042025-11-040000078003pfe:NotesDue20271.000Member2025-11-042025-11-040000078003pfe:NotesDue20292.875Member2025-11-042025-11-040000078003pfe:NotesDue20323.250Member2025-11-042025-11-040000078003pfe:NotesDue20373.875Member2025-11-042025-11-040000078003pfe:NotesDue20454.250Member2025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 4, 2025

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware			1-3619			13-5315170
(State or other			(Commission File			(I.R.S. Employer
jurisdiction of			Number)			Identification No.)
incorporation)

66 Hudson Boulevard East						10001-2192
New York,			New York			(Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code:

(212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.05 par value

PFE

New York Stock Exchange

1.000% Notes due 2027

PFE/27

New York Stock Exchange

2.875% Notes due 2029

PFE/29

New York Stock Exchange

3.250% Notes due 2032

PFE/32

New York Stock Exchange

3.875% Notes due 2037

PFE/37A

New York Stock Exchange

4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 2.02 Results of Operations and Financial Condition

On November 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.

The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)  Exhibits

Exhibit Number						Exhibit Description
Exhibit 99						Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

EXHIBIT INDEX
Exhibit No.						Description
99						Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PFIZER INC.
			By:			/s/ Margaret M. Madden
						Margaret M. Madden
						Senior Vice President and Corporate Secretary
						Chief Governance Counsel

Dated: November 4, 2025

FAQ

What did PFE file on November 4, 2025?

Pfizer filed an 8-K furnishing a press release with its Q3 2025 financial results as Exhibit 99.

Which item covers Pfizer’s Q3 2025 results?

The results are disclosed under Item 2.02 (Results of Operations and Financial Condition).

Is the Q3 2025 press release considered filed or furnished?

It is furnished, not filed, and not subject to Section 18 of the Exchange Act.

Where can I find the detailed numbers for Pfizer’s Q3 2025?

They are in the press release attached as Exhibit 99 to the 8-K.

What additional exhibit accompanies the filing?

The filing includes Exhibit 104, the Inline XBRL cover page data file.

What is Pfizer’s trading symbol?

Pfizer’s common stock trades on the NYSE under the symbol PFE.